Oramed COO & CBO Joshua Hexter sells $135,330 in shares

Joshua Hexter, Chief Operating Officer and Chief Business Officer of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), sold 30,000 shares of common stock on October 1, 2026. The transactions, executed under a Rule 10b5-1 trading plan adopted on March 30, 2026, totaled $135,330.

The shares were sold at prices ranging from $4.440 to $4.650, with a weighted average price of $4.511 per share. The sale comes after a strong performance period for Oramed stock, which has delivered a 92% return over the past year and gained 31% in the last six months. Following these sales, Mr. Hexter directly owns 1,328,130 shares of Oramed Pharmaceuticals Inc. common stock. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company offering a 5.6% dividend yield. Investors can access 10 additional ProTips and comprehensive financial metrics on the platform.

In other recent news, Oramed Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved all six proposals presented. The meeting included the re-election of directors Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, and Benjamin Shapiro. These directors will serve until the next annual meeting or until successors are elected. The vote tallies for each director in favor ranged from 11,567,510 to 13,702,335, with opposition votes ranging from 3,729,485 to 5,859,953. This approval marks a continuation of the current leadership team, reflecting shareholder confidence in the company’s direction. The board’s composition remains unchanged as a result of these decisions.